AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsTechnology, Industry, AgricultureNamed GroupsHealth Care
Intravitreal InjectionsVitreous BodyInjectionsTriamcinolone AcetonideEndophthalmitisInjections, IntraocularAngiogenesis InhibitorsRetinaMacular EdemaFluorescein AngiographyElectroretinographyAntibodies, Monoclonal, HumanizedVisual AcuityChoroidal NeovascularizationTriamcinoloneRetinal NeovascularizationRetinal Vein OcclusionAqueous HumorLaser CoagulationFundus OculiRetinal DiseasesDiabetic RetinopathyTreatment OutcomeRetinitisVitrectomyVitreous DetachmentRetinal Ganglion CellsRetinal VesselsBlood-Retinal BarrierRabbitsVitreoretinopathy, ProliferativeMacular DegenerationFluorophotometryRetinal HemorrhageWet Macular DegenerationRetinal DetachmentTomography, Optical CoherenceVascular Endothelial Growth Factor AEye DiseasesGlaucoma, NeovascularGlucocorticoidsIntraocular PressureEyeEye Infections, BacterialChoroidRetinal DegenerationCytomegalovirus RetinitisOptic Nerve InjuriesDisease Models, AnimalOphthalmoscopyRadioactivityLeukostasisMyopia, DegenerativeEye Infections, ViralRetinopathy of PrematurityUveitis, PosteriorUveitisEye PainPhotoreceptor Cells, VertebrateRetinal Pigment EpitheliumOutcome Assessment (Health Care)Macula LuteaRetinal TelangiectasisChoroid DiseasesRats, Inbred BNAntibodies, MonoclonalTime FactorsOptic NerveRetrospective StudiesFollow-Up StudiesAnti-Inflammatory AgentsOcular HypertensionCiliary BodyFovea CentralisProspective StudiesPigment Epithelium of EyeDependovirusMacaca fascicularisUveitis, AnteriorCell CountFluorescent Antibody Technique, IndirectPlasma KallikreinStreptococcus mitisHalf-LifeAnterior ChamberCiliary Neurotrophic FactorInjections, IntravenousIndocyanine GreenOcular HypotensionRats, Sprague-DawleyOphthalmic SolutionsPregnancy OutcomeDrug Administration RoutesGanciclovirDose-Response Relationship, DrugIn Situ Nick-End LabelingEye ProteinsInjections, IntramuscularN-MethylaspartatePipecolic Acids
RetinalMacularPhotodynamic therapyTriamcinolone acetonide injectionNeovascularBevacizumab injectionsDexamethasone intravitreal implantPhotocoagulationPatientsRanibizumab intravitrealImplantVitrectomyEfficacyTreatmentFluorescein AngiographyOcularStatistically significantSecondaryOcclusionAflibercept injectionRetinopathy of prematurCataract surgeryPovidone-iodineCorticosteroidsBaselineAvastinBCVAIntraocular injectionEvaluatePotent1.25 mgAntibioticSafety outcomesClinical outcomesPrimary outcomeEndophthalmitis ratesTreatmentsFewerVisual
Retinal18
Macular19
  • Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. (medscape.com)
  • Kaiser PK, Boyer DS, Garcia R, Hao Y, Hughes MS. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. (medscape.com)
  • Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. (medscape.com)
  • By further selecting patients with CNV who had accepted their last intravitreal injection of bevacizumab within 3 months, the level of IL-6 still significantly correlated with the maximum macular thickness (p=0.019) and macular volume within 1 mm (p=0.018), 3 mm (p=0.018), and 6 mm (p=0.022). (molvis.org)
  • This study included 17 patients (17 eyes) with exudative AMD, ten patients (ten eyes) with pathological myopia (PM), seven patients (seven eyes) with idiopathic choroidal neovascularization (CNV) who underwent intravitreal injection of bevacizumab (Avastin, Genentech Inc., San Francisco, CA) as the study group, and 14 patients (14 eyes) with cataract and idiopathic epiretinal membrane or a macular hole who underwent combined cataract and vitrectomy surgery (CCVS) as the control group. (molvis.org)
  • Intravitreal injections (IVT) are used worldwide to treat age-related macular degeneration, and macular oedema. (arvojournals.org)
  • Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. (mdfoundation.com.au)
  • Intravitreal injections of antiangiogenic agents are pivotal in treating neovascular age-related macular degeneration (nAMD). (mdfoundation.com.au)
  • Intravitreal anti-vascular endothelial growth factor (VEGF) injection demonstrated a significant improvement in vision with resolution of macular edema and reversed the underlying diabetic retinopathy (DR) severity in patients with diabetic macular edema (DME). (bmj.com)
  • To investigate factors affecting patient response to intravitreal ranibizumab treatment for age-related macular degeneration (AMD). (nih.gov)
  • Introduction The purpose was to compare two flexible regimens of intravitreal aflibercept (IVT-AFL) with fixed dosing every 8 weeks, beyond the first year of treatment, in patients with diabetic macular edema (DME). (unimi.it)
  • T hough intravitreal anti-vascular endothelial growth factor agents are the mainstay of treatment for neovascular age-related macular degeneration, frequent and repeated injections are required in order to maintain the visual gains the drugs provide. (reviewofophthalmology.com)
  • PURPOSE OF REVIEW: Intravitreal anti-vascular endothelial growth factor (VEGF) agents are used routinely in the management of neovascular conditions including proliferative diabetic retinopathy and diabetic macular edema. (bvsalud.org)
  • Intravitreal anti-VEGF therapy is used in the treatment of diabetic retinopathy, macular degeneration, and other diseases. (bvsalud.org)
  • Shu Y, Ye F, Liu H, Wei J, Sun X. Predictive value of pigment epithelial detachment markers for visual acuity outcomes in neovascular age-related macular degeneration. (consultantlive.com)
  • Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment. (docksci.com)
  • ABSTRACT Purpose: To evaluate the safety and efficacy of intravitreal dexamethasone implant (Ozurdex) in patients with chronic diabetic macular edema (DME) resistant to prior intravitreal bevacizumab (IVB) treatment. (docksci.com)
  • A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. (medscape.com)
  • A retrospective chart review was performed for 71 eyes of 67 patients with neovascular age-related macular degeneration (AMD) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections using a treat-extend-stop protocol. (medscape.com)
Photodynamic therapy6
  • Treatment modalities for CSC include focal laser photocoagulation, photodynamic therapy (PDT), and intravitreal anti-vascular endothelial growth factor (VEGF) injections [ 14 ]. (plos.org)
  • Although the DENALI and MONT BLANC trials did not show a significant benefit of adding photodynamic therapy to anti-VEGF therapy in new-onset neovascular AMD, several others have shown that combination therapy did require fewer anti-VEGF injections. (medscape.com)
  • The management of CNV secondary to angioid streaks with intravitreal anti-vascular endothelial growth factor (VEGF) injections, irrespective of the molecule (i.e., bevacizumab, ranibizumab, or aflibercept), has shown superior functional and morphologic results compared with previous therapeutic options, such as photocoagulation laser and photodynamic therapy (PDT). (hindawi.com)
  • PURPOSE: The aim of this study is to discuss the effect and outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab (1.25 mg) in occult and classic choroidal neovascularisation (CNV) due to AMD. (tum.de)
  • CONCLUSIONS: Photodynamic therapy combined with injection of intravitreal bevacizumab tends to be more effective compared to PDT monotherapy by reducing the post-PDT increase of vascular growth and inflammatory factors. (tum.de)
  • treatment options include intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections or photodynamic therapy (PDT). (cdc.gov)
Triamcinolone acetonide injection1
Neovascular2
  • At the third and twelfth months after injection, VA was better in PCV than in typical neovascular AMD (P = .027 and P = .044, respectively), although there were no differences in baseline VA between the 2 groups. (nih.gov)
  • 5 , 7 , 8 Why some patients have a poor response to ranibizumab is not well understood, but use of indocyanine green angiography (ICGA) has revealed the presence of polypoidal choroidal vasculopathy (PCV) in several patients with neovascular AMD who did not respond to repeated injections of anti-VEGF agents. (bmj.com)
Bevacizumab injections2
  • To investigate long-term treatment response after intravitreal bevacizumab injections (IVBIs) for central serous chorioretinopathy (CSC). (plos.org)
  • Kang HM, Choi JH, Koh HJ, Lee SC (2020) Long-term treatment response after intravitreal bevacizumab injections for patients with central serous chorioretinopathy. (plos.org)
Dexamethasone intravitreal implant1
  • Conclusion: Dexamethasone intravitreal implant may be an effective and safe alternative in treatment of chronic DME nonresponsive to regular IVB. (docksci.com)
Photocoagulation3
  • Secondary outcomes were the need for intravitreal injections, panretinal photocoagulation (PRP), or pars plana vitrectomy (PPV). (medscape.com)
  • This is a multicenter retrospective cohort study, which included eyes with CNV secondary to angioid streaks treated with intravitreal anti-VEGF injections (with or without previous alternative treatments, such as laser photocoagulation or PDT). (hindawi.com)
  • The aim of this study was to compare the cardiac effects and aortic arterial indices followingintravitreal aflibercept treatment or diode laser photocoagulation for the treatment of retinopathy of prematurity (ROP) in infants.Methods:This single-centre, retrospective study was conducted in infants who were administered laser photocoagulation (LPC) or intravitreal aflibercept (IVA) treatment as initialtreatment and had completed at least one year of corrected age. (bvsalud.org)
Patients51
  • The main outcome measure was long-term treatment outcome after IVBIs in patients with CSC. (plos.org)
  • Patients received intravitreal injection of ACP, a C5 inhibitor, every month for an 18-month course. (aao.org)
  • CHICAGO - All but one of 12 patients given injections of contaminated bevacizumab (Avastin) prepared by a compounding pharmacy in Florida permanently lost vision in the affected eye, researchers reported here. (medpagetoday.com)
  • Neither early nor late vitrectomy improved visual outcomes, and seven patients lost the eye completely in the endophthalmitis outbreak that occurred in Miami in July 2011, Roger Goldberg, MD, of the New England Eye Center at Tufts University, and colleagues reported at the American Academy of Ophthalmology meeting. (medpagetoday.com)
  • In the Miami endophthalmitis outbreak, Goldberg said 12 patients arrived in the ophthalmic emergency department within 6 days of getting an intravitreal injection of bevacizumab - nine of them arrived within 48 hours of having the shots. (medpagetoday.com)
  • Goldberg told MedPage Today that with the rise of expensive, branded intravitreal anti-VEGF agents that come in appropriate doses, such as ranibizumab (Lucentis), the "need for Avastin syringes safely aliquoted from 4- or 16-mL vials into the tiny doses used in the eye has further increased our reliance on compounding pharmacies and the critical role they play in the care of our patients. (medpagetoday.com)
  • The aqueous level of all cytokines did not vary significantly between the CNV patients who had accepted their last intravitreal injection of bevacizumab within 3 months and the other patients, nor was a difference found among patients with exudative AMD, PM, and idiopathic CNV, and the control group. (molvis.org)
  • However, in addition to anti-VEGF pharmacotherapy, intravitreal administered anti-inflammatory substances, such as triamcinolone acetonide (TA) [ 11 - 13 ], a widely used anti-inflammatory drug, and infliximab [ 14 ], an antibody of tumor necrosis factor α (TNF- α), have also shown positive effects in treating CNV in patients and animal models. (molvis.org)
  • This study describes its clinical spectrum, management outcomes and genetic associations in patients with autosomal recessive RP (arRP). (lu.se)
  • Materials and methods: Retrospective review of ophthalmic, multimodal imaging, genetic findings and treatment outcomes of arRP patients who developed Coats-like features. (lu.se)
  • Does repeated intravitreal injections impact the quality of life of patients, about 40 patients? (arvojournals.org)
  • Patients report symptoms (ocular pain and burning) that appear within hours of injection, which have an impact on their daily activities. (arvojournals.org)
  • Patients were assessed during two consultations: one before injection, with a clinical exam (presence of keratitis evaluated by Oxford classification), an automated evaluation of corneal surface using Lacrydiag® and the achievement of an OSDI score (ocular surface disease index). (arvojournals.org)
  • Repeated intravitreal injections induced clinical discomfort in our patients and altered their quality of life by modifying the corneal surface. (arvojournals.org)
  • Total of 40 intra-vitreal injections of Avastin were given to patients with a mean of 2.35 injections per eye. (pakmedinet.com)
  • A prospective randomized control trial of 140 eyes from 140 patients, who underwent phacoemulsification, was conducted to compare the efficacy of subtenon corticosteroids injection with corticosteroids eye drops for controlling postoperative intraocular inflammation. (springer.com)
  • Seventy patients received subtenon 20-mg triamcinolone injection (TA group), whereas the other 70 patients received 0.1% dexamethasone eye drops (Dexa group) after the uneventful surgeries. (springer.com)
  • Therefore, a single subtenon triamcinolone injection could be an alternative treatment to control inflammation after cataract surgery, especially in patients with poor drug compliance 12 . (springer.com)
  • METHODS: In a pilot study involving 23 patients, intravitreal injections of bevacizumab were administered within 12 to 24 hours after standard PDT to reduce the post-PDT increase of proangiogenic and inflammatory factors. (tum.de)
  • METHODS: In a pilot study involving 23 patients, intravitreal injections of. (tum.de)
  • 2 Unfortunately, the need for frequent injections can often pose problems to treatment adherence and cause patients to be lost to follow-up. (reviewofophthalmology.com)
  • The primary outcome is the proportion of patients with no disease activity at week 48. (reviewofophthalmology.com)
  • 3-7 OCT images have shown that, in most patients, resolution of intraretinal and subretinal fluid (the presence of which corresponds with a decrease in BCVA) can be achieved 1-3 months after the start of monthly ranibizumab injections, often followed by an injection-free interval of several months before fluid begins to reaccumulate. (bmj.com)
  • 5 , 7 , 8 However, some patients continue to require frequent injections. (bmj.com)
  • STUDY SELECTION: Eligible studies reporting on patients who received IVIs with anti-VEGF drugs with a clearly stated injection setting of the office or OR. (bvsalud.org)
  • Patients also could continue to receive pegcetacoplan injections safely while anti-VEGF injections were initiated. (medscape.com)
  • We will also learn about the initiative of the medical retina team and its Nurse Counsellors in using an interactive patient education platform to educate patients of the importance of Intravitreal injection therapy in AMD so as to improve patient compliance and treatment outcomes. (snec.com.sg)
  • PURPOSE: The purpose of this study is to evaluate clinical outcomes of autoimmune retinopathy (AIR) in the patients treated with intravitreal dexamethasone implant (IDI). (bvsalud.org)
  • METHOD: Twenty-one eyes of 11 AIR patients treated with at least 1 injection of IDI were retrospectively reviewed. (bvsalud.org)
  • CONCLUSION: Clinical outcomes, including BCVA and parameters of OCT, ERG, and VF, were stable or improved after IDI in a majority of AIR patients. (bvsalud.org)
  • RESULTS: During the COVID-19 lockdown 198 eyes (82.5%) of 157 patients (82.6%) received their injections in a timely manner (group 1) while 42 eyes (17.5%) of 33 patients (17.4%) had their injections delayed or missed (group 2). (bvsalud.org)
  • The BCVA and rate of complications at 1 year did not differ whether patients missed their scheduled injections or not. (bvsalud.org)
  • Historically, PED has served as a valuable prognosticator for poor visual outcomes among patients with nAMD receiving anti-VEGF treatment, investigators wrote. (consultantlive.com)
  • In contrast, quantitative morphological parameters for PED had no predictive effect on the short- and long-term BCVA gains for PCV patients with intravitreal injection of conbercept. (consultantlive.com)
  • Though the BCVA gain of treated nAMD patients with PCV was less than that of those without PCV, the difference in outcome was not significant. (consultantlive.com)
  • The reasons for endophthalmitis were previous cataract surgery in 78 patients and following intravitreal injection in 38 patients. (biomedcentral.com)
  • The main objectives of this retrospective multi-center study were to evaluate the rate, risk factors, functional outcome and prognosis of RD after surgical treatment of patients with severe acute exogenous postoperative endophthalmitis having no BCVA exclusion criteria. (biomedcentral.com)
  • A total of 362 patients (305 patients with CRVO and 57 with HRVO) were randomly assigned to receive intravitreal injections of aflibercept 2.0mg or bevacizumab 1.25mg at randomization and every four weeks through month five. (reviewofoptometry.com)
  • Materials and Methods: Thirty eyes of 30 patients were administered intravitreal Ozurdex and examined at baseline and 1, 3, and 6 months postinjection in this prospective study. (docksci.com)
  • Patients had a CFT over 275 mm (measured by OCT) and were unresponsive to 3 consecutive IVB injections. (docksci.com)
  • METHODS: A total of 191 patients with exudative ARMD were randomly assigned to a 1-year continuous regimen of intravitreal bevacizumab every 4 (n = 64), 6 (n = 63) or 8 weeks (n = 64). (eyehospital.nl)
  • In this study, we set out to determine whether bevacizumab treatment in exudative ARMD every 6 or 8 weeks is non-inferior to bevacizumab treatment every 4 weeks.METHODS: A total of 191 patients with exudative ARMD were randomly assigned to a 1-year continuous regimen of intravitreal bevacizumab every 4 (n = 64), 6 (n = 63) or 8 weeks (n = 64). (eyehospital.nl)
  • Patients then received two injections at 12-week intervals. (medscape.com)
  • The study included patients only if they had received at least 50 intravitreal anti-VEGF injections. (medscape.com)
  • These patients had a similar number of injections (63.7) as the rest of the patients. (medscape.com)
  • This was a well-designed retrospective review of long-term visual outcomes of patients with wet AMD treated with intravitreal anti-VEGF agents using a treat-extend-stop protocol. (medscape.com)
  • Of note, this study showed a small number of patients with central geographic atrophy even after an average of nearly 65 injections. (medscape.com)
  • It is worth noting that this study excluded patients receiving fewer than 50 injections. (medscape.com)
  • The rate of geographic atrophy in patients receiving fewer than 50 injections would be important to know, because these patients may have stopped therapy because they were deemed untreatable. (medscape.com)
  • Not including patients with at least 50 injections also may have excluded those with disciform scars or even patients who had responded well to treatment but did not require further injections. (medscape.com)
  • Still, it is perhaps the longest of any study currently in the literature of its kind and highlights the positive long-term visual outcomes in patients with wet AMD using a treat-extend-stop protocol. (medscape.com)
Ranibizumab intravitreal1
  • 1 The widespread use of ranibizumab intravitreal injection for the treatment of this condition was based on results from the pivotal Phase III Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neo-vas-cular AMD (MARINA) and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularisation in AMD (ANCHOR) studies. (bmj.com)
Implant2
  • The purpose of this review article is to provide a comprehensive review of the current applications of intravitreal DEX implant (Ozurdex ® , Allergan Inc, Irvine, CA) for a variety of ophthalmic conditions - ranging from FDA approved indications to off-label uses. (dovepress.com)
  • Intravitreal dexamethasone implant (DEX implant, Ozurdex ® , Allergan Inc, Irvine, CA) is a rod-shaped implant made of a solid biodegradable polymer (Novadur™, Allergan Inc, Irvine, CA) designed to release 700 micrograms of preservative-free dexamethasone over a period of 180 days. (dovepress.com)
Vitrectomy2
Efficacy2
  • A systematic review and meta-analysis of English-language RCTs reporting on efficacy and/or safety outcomes of dosing regimens of anti-VEGF agents in nAMD was performed. (mdfoundation.com.au)
  • However, its therapeutic efficacy decreases between the third and sixth months following the injection. (docksci.com)
Treatment23
  • For people with suspected exogenous endophthalmitis, a biopsy (virtuous tap) and treatment with antibiotics (usually by injection) is usually the first line of treatment. (wikipedia.org)
  • The first step in treatment (usual care) is an intravitreal injection of potent antibiotics and a biopsy to determine the type of infection. (wikipedia.org)
  • Intravitreal injection therapy using anti-vascular endothelial growth factor (VEGF) agents is considered first-line treatment for AMD . (medscape.com)
  • Early diagnosis and treatment initiation, particularly with VEGF agents, has been shown to improve visual and anatomic outcomes . (medscape.com)
  • The number of intravitreal injections received by the group during their treatment period ranged from 1 to 6 injections, with both the mean and median being 3 injections. (annals.edu.sg)
  • A single subtenon 20-mg triamcinolone injection could be an alternative anti-inflammatory treatment for an uneventful phacoemulsification. (springer.com)
  • This study aimed to evaluate the long-term effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) injections in the treatment of choroidal neovascularization (CNV) associated with angioid streaks. (hindawi.com)
  • Therefore, the primary endpoint of this study was to evaluate the effectiveness of intravitreal anti-VEGF injections at 48 months in the treatment of CNV associated with angioid streaks in a real-world study. (hindawi.com)
  • We reviewed medical records of 105 consecutive eyes with AMD treated with intravitreal ranibizumab injections and followed for more than 1 year after treatment. (nih.gov)
  • Conclusion The treatment burden associated with intravitreal injections for DME is lowest with T&E regimens, but there are a range of flexible IVT-AFL dosing regimens, allowing physicians to adopt an individualized treatment plan. (unimi.it)
  • Real World Treatment Outcomes in Polypoidal Choroidal Vasculopathy in a Caucasian Population of British Ethnicity. (researchsquare.com)
  • The aim of this review is to discuss the most recent literature reports regarding the various ocular and systemic adverse events associated with intravitreal anti-VEGF treatment in diabetic retinopathy. (bvsalud.org)
  • Subconjunctival hemorrhage and vitreous hemorrhage are the most common ocular adverse events reported with intravitreal anti-VEGF treatment. (bvsalud.org)
  • As the first report of PVE in the Southeast Asian population, the present study aimed to describe the incidence, clinical characteristics, and treatment outcomes of PVE in the Thai population. (biomedcentral.com)
  • One patient with an at-risk optic disc on monthly treatment developed ischemic optic neuropathy after six injections. (medscape.com)
  • Clinical outcomes before and after treatment, including best corrected visual acuity (BCVA), optic coherence tomography (OCT), fundus autofluorescence (FAF), full-field electroretinography (ff-ERG), and visual field (VF) at last visit within 6 and/or 12 months, were recorded. (bvsalud.org)
  • According to data from an analysis of patient eyes with nAMD, baseline PED provided notable predictive value in interpreting treatment outcomes with conbercept among those without polypoidal choroidal vasculopathy (PCV). (consultantlive.com)
  • The primary outcome was visual acuity change after 1 year of treatment. (eyehospital.nl)
  • The primary outcome was visual acuity change after 1 year of treatment.RESULTS: In all three treatment groups, visual acuity improved between baseline and 1 year. (eyehospital.nl)
  • Consequently, we observed only minor differences between the treatment groups, which may suggest subtle changes due to the anti-angiogenictreatment.Conclusion:Although favourable and promising outcomes were obtained with intravitreal injection of anti-vascular endothelial growth factor agents for the treatment of ROP,concerns have been raised about potential systemic side effects, including potential cardiovascular side effects caused by these agents. (bvsalud.org)
  • If, after this initial series, the macula was found to be without fluid, then the treatment was extended by 1- to 2-week intervals until a 12-week interval between injections was achieved. (medscape.com)
  • The mean initial visual acuity was 55.6 Early Treatment Diabetic Retinopathy Study (EDTRS) letters (20/80 Snellen acuity), and the mean acuity at the 50th injection was 65.3 EDTRS letters (20/50 Snellen acuity). (medscape.com)
  • For people who have vision loss from POHS, injections into the eye with a treatment called anti-vascular endothelial growth factor can help. (cdc.gov)
Fluorescein Angiography1
  • In this prospective case series, the nonperfusion index assessed by ultrawide field fluorescein angiography was significantly decreased at 6 months (p=0.015) after 6 monthly injections of aflibercept and then slightly increased (p=0.123) after 6 months of observation. (bmj.com)
Ocular2
  • Secondary outcomes were to determine whether injections impact the ocular surface, comparing the injected eye and the fellow eye (control eye). (arvojournals.org)
  • Best-corrected visual acuity (BCVA, ETDRS letters) at last follow-up represented the primary endpoint, while central subfield thickness (CSFT, μm), injection burden, and ocular adverse events were secondary endpoints. (mdfoundation.com.au)
Statistically significant1
Secondary4
Occlusion1
  • Dose of 0.05 ml (1.25mg) of Avastin (Bevacizumab) was used as intra vitreal injection every month for 3 months in cases that presented within a month of occlusion and less injections were given in dose presenting later. (pakmedinet.com)
Aflibercept injection1
Retinopathy of prematur1
  • Refractive and Biometric Outcomes Following Intravitreal Injection of Ranibizumab in Retinopathy of Prematurity: A Long -Term Study. (researchsquare.com)
Cataract surgery4
  • Moderate evidence also supports antibiotic eye drops (levofloxacin or chloramphenicol) with antibiotic injections (cefuroxime or penicillin) to reduce the risk of endophthalmitis after cataract surgery compared with injections or eye drops alone. (wikipedia.org)
  • Periocular injection of penicillin along with chloramphenicol-suphadimidine eye drops and an intracameral cefuroxime injection with topical levofloxacin also reduces the risk reduction of developing endophthalmitis following cataract surgery for some people. (wikipedia.org)
  • As technology evolves, cataract surgery outcomes also continue to improve. (aao.org)
  • Outcomes after femtosecond laser cataract surgery. (aao.org)
Povidone-iodine3
Corticosteroids2
  • In comparison, subtenon injection of depot corticosteroids is easy and safe. (springer.com)
  • The effect lasts for 4-6 weeks after a single injection, making this procedure possible to replace topical corticosteroids. (springer.com)
Baseline1
  • There were, however, an additional 30 eyes (42.3%) that had decreased visual acuity from baseline at the time of the 50th injection and six (8.5%) that lost three lines or more. (medscape.com)
Avastin1
  • Ophthalmologists are "very reliant on compounding pharmacies, not just for Avastin but for all preservative-free formulations and intravitreal antibiotics," said Goldberg, who was working at the University of Miami when the outbreak occurred. (medpagetoday.com)
BCVA2
  • The results confirmed that the PEDV could predict the short- and long-term BCVA gains for non-PCV after intravitreal injection of conbercept," investigators wrote. (consultantlive.com)
  • Main outcomes were the best corrected visual acuity (BCVA, logMAR), central foveal thickness (CFT), mean cube volume (MCV), and intraocular pressure (IOP). (docksci.com)
Intraocular injection1
  • 14 days after they received intraocular injection with bevacizumab that had been repackaged at pharmacy A after December 18, 2012. (cdc.gov)
Evaluate1
  • OBJECTIVE: To evaluate the safety outcomes of IVI with anti-VEGF agents in the OR vs office-based setting. (bvsalud.org)
Potent1
  • Dexamethasone is a potent water-soluble glucocorticoid that was first administered by intravitreal injection as an adjunct in experimental endophthalmitis as early as in 1974 with beneficial results. (dovepress.com)
1.25 mg1
  • compounding pharmacies repackage bevacizumab into syringes for intraocular administration at smaller doses (e.g., 1.25 mg bevacizumab in 0.05-mL injection). (cdc.gov)
Antibiotic1
Safety outcomes1
  • There was no significant difference in safety outcomes amongst comparators. (mdfoundation.com.au)
Clinical outcomes1
  • IMPORTANCE: Compared with the operating room (OR), office-based intravitreal injection (IVI) is considered a more cost-effective and convenient approach, yet clinical outcomes of IVIs with anti-vascular endothelial growth factor (VEGF) agents in different settings (office-based vs OR) have not been systematically evaluated. (bvsalud.org)
Primary outcome1
  • The primary outcome was the difference in the OSDI score before and after IVT. (arvojournals.org)
Endophthalmitis rates1
  • Dr Garg presented data from a recent retrospective study that evaluated universal face mask use on post-injection endophthalmitis rates, a practice that has increased during the COVID-19 pandemic. (ophthalmology360.com)
Treatments1
  • A consensus regarding the association of systemic adverse events (such as myocardial infarction, stroke, and death) with intravitreal anti-VEGF treatments has not been established. (bvsalud.org)
Fewer1
Visual3
  • Visual outcome was defined as Snellen's or LogMar Best Corrected Visual Acuity at final follow up, of 120th day, compared to the visual acuity at presentation. (pakmedinet.com)
  • Good visual outcome was achieved in 10(58.8%) eyes, while 7(41.2%) had stable visual outcome. (pakmedinet.com)
  • 001). At the time of the 50th injection, 30 eyes (42.9%) had visual acuity of 20/40 or better. (medscape.com)